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Abstract  27 
SARS-CoV-2 infects multiple organs including the respiratory tract and gut. Whether regional 28 
microbiomes are disturbed significantly to affect the disease progression of COVID-19 is largely 29 
unknown. To address this question, we performed cross-sectional and longitudinal analyses of throat 30 
and anal swabs from 35 COVID-19 adults and 15 controls by 16S rRNA gene sequencing. The results 31 
allowed a partitioning of patients into 3-4 categories (I-IV) with distinct microbial community types 32 
in both sites. Lower-diversity community types often appeared in the early phase of COVID-19, and 33 
synchronous fast restoration of both the respiratory and gut microbiomes from early dysbiosis towards 34 
late near-normal was observed in 6/8 mild COVID-19 adult patients despite they had a relatively slow 35 
clinical recovery. The synchronous shift of the community types was associated with significantly 36 
positive bacterial interactions between the respiratory tract and gut, possibly along the airway-gut 37 
axis. These findings reveal previously unknown interactions between respiratory and gut 38 
microbiomes, and suggest that modulations of regional microbiota might help to improve the recovery 39 
from COVID-19 in adult patients.  40 
 41 
Keywords: SARS-CoV-2/COVID-19; respiratory microbiota; gut microbiota, dysbiosis; adults; co-42 
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Introduction 44 
COVID-19, a severe respiratory disease caused by a novel virus SARS-CoV-21,2, has led to a devastating 45 
global pandemic. It typically presents as asymptomatic infection and mild respiratory symptoms, but 46 
in those older than 60 years or having comorbidities, COVID-19 can develop into severe pneumonia 47 
and cause death3,4. The biological mechanisms behind the varied clinical presentation of disease are 48 
not fully understood. Because the microbiota plays a major role in the maintenance of human health 49 
by shaping the immune system and maintaining homeostasis5, and the microbial composition in the 50 
respiratory tract and the gut have been linked to the occurrence and severity of various respiratory 51 
viral infections, and affects subsequent respiratory health6,7, such as increased airway susceptibility 52 
to infection by other RVs and/or colonization of pathogenic bacteria8-10, it is reasonable to posit that 53 
the new respiratory infection COVID-19 may also interact with microbiota.  54 
Recent studies show that SARS-CoV-2 infects human gut enterocytes and causes diarrhea11,12, 55 
and COVID-19 patients have altered gut microbiota featuring an enrichment of opportunistic 56 
pathogens and a depletion of beneficial bacteria13,14. However, the effect of COVID-19 on respiratory 57 
microbiome has never been evaluated. Although one study reported persistent alterations in the gut 58 
microbiota using longitudinal stool samples collected during COVID-19 patients’ hospitalization13, 59 
but no study has been performed to simultaneously investigate the temporal dynamics of both the 60 
respiratory and gut microbiota at various stages of disease. In this study, we investigated the dynamics 61 
of both the respiratory and gut microbiomes in a cohort of COVID-19 patients and controls, and 62 
presented a consistent pattern of changes in these two organs from early dysbiosis towards late 63 
incomplete restoration in the majority of COVID-19 adults.  64 
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Results 65 
Study cohort  66 
The study subjects included 35 adult COVID-19 patients from 17 to 68 years of age, 15 healthy 67 
adults, and 10 non-COVID-19 patients with other diseases. All COVID-19 patients (except patient 68 
p09) had mild clinical symptoms. A total of 146 specimens including 37 pairs of both throat and anal 69 
swabs were collected from COVID-19 patients (Supplementary Fig. S1). High-throughput 70 
sequencing of the V4-region of bacterial 16S rRNA gene was performed for all samples (See 71 
Supplementary Methods). 72 
 73 
Respiratory microbiome dynamics in COVID-19  74 
The 16S-rRNA gene sequences of all throat swabs were resolved into 3,126 amplicon sequence 75 
variants (ASVs) representing 17 known phyla including 209 known genera (Supplementary Table 76 
S1). Six throat microbial community types (or clusters) were identified using the Dirichlet 77 
Multinomial Mixtures (DMM) modelling based on lowest Laplace approximation (Fig. 1a) and 78 
visualized by Nonmetric Multidimensional Scaling (NMDS) based on Bray-Curtis distance (Fig. 1b). 79 
Healthy adults (H) and non-COVID-19 patients (NP) formed independent clusters. The vast majority 80 
of the specimens of COVID-19 patients were divided into four community types, called I-IV, and 6 81 
specimens were included in the NP type (Fig. 1a). All COVID-19-related community types, as well 82 
as the NP type, were significantly separated from the H type. Community types III and IV were not 83 
only significantly separated from the types I and II, but also from each other (Fig. 1b). Consistently, 84 
significantly lower richness and evenness were observed in community types III and IV, compared 85 
with the H type (Fig. 1c).  86 
To more directly demonstrate that the variation of throat microbial composition is an indicator 87 
of COVID-19 disease stages, the community type-specific indicator taxa were identified based on the 88 
top 30 microbial genera (Fig. 1d). The type H was characterized by bacterial genus Bacteroides 89 
(predominant taxa in the lung of healthy individuals) and unclassified Comamonadaceae, whereas 90 
the NP type was marked by pro-inflammatory Enterobacteriaceae members. In contrast, the indicator 91 
bacteria of four COVID-19-related community types were Alloprevotella in I, Porphyromonas, 92 
Neisseria, Fusobacterium and unclassified Bacteroidales in II, Pseudomonas in III, and 93 
Saccharibacteria incertae sedis, Rothia and unclassified Actinomycetales in IV (Fig. 1d). It is clear 94 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 22, 2020. ; https://doi.org/10.1101/2020.07.21.20158758doi: medRxiv preprint 
that the indicators in the types III and IV belong to putative pathogenic (e.g. Pseudomonas) and 95 
opportunistic pathogenic bacteria (e.g. Rothia). Community type I contained Alloprevotella genus, as 96 
well as abundant Bacteroides and Prevotella that typically present in the H type (Fig.1a). Pathogenic 97 
bacteria Pseudomonas, Saccharibacteria incertae sedis and Rothia that are associated with 98 
pneumonia and various human diseases were significantly enriched in community types III and IV, 99 
reflecting an impaired microbiome (dysbiosis) in the respiratory tract15-17. Apart from beneficial 100 
commensals (e.g. Bacteroidales), some opportunistic pathogenic bacteria such as Porphyromonas, 101 
Fusobacterium, and Neisseria that typically exist in the nasopharynx, and are associated with 102 
pneumonia or chronic periodontitis18-20, were over represented in type II, possibly reflecting an 103 
intermediate state between the normal and dysbiosis in the respiratory microbiota (Supplementary 104 
Table S1 and Fig. S2). According to indicator characteristics, community types I to IV reflected a 105 
progressive imbalance of the respiratory microbiome. 106 
Longitudinal analysis showed that lower-diversity community types often appeared in early 107 
specimens (Fig. 1e), and throat microbiota was dominated by few putative pathogenic and 108 
opportunistic bacteria at the early phase of COVID-19 (Supplementary Fig. S2). Prominent 109 
microbiome community type shifts from early lower-diversity community types (NP, IV or II) 110 
towards later higher-diversity types (II or I) were observed in 9/24 COVID-19 adults who had 111 
specimens at two or more time points. For example, an obvious throat microbiome progression from 112 
type (IV or II) in early specimens to type I in late specimens was observed in five patients (p17, p25, 113 
p13, p11 and p05) with 4 or more consecutive specimens (Fig. 1e). Accompanied with the restoration 114 
of throat microbiota, beneficial commensals appeared to occupy the niches, and the bacterial diversity 115 
increased accordingly (Supplementary Fig. S2). However, a reversed pattern was observed in four 116 
patients who had microbiome composition shift from early higher-diversity types (I or II) to later 117 
lower-diversity type (II-IV), implying a worsening of the throat microbiome. For example, in the only 118 
severe case (p09), the community type II on day 10 was shifted to type IV on day 27, and sustained 119 
to at least day 33 after symptom onset (Fig. 1e), and pathogenic bacteria Saccharibacteria incertae 120 
sedis and Rothia were significantly enriched at late stage (Supplementary Fig. S2). Furthermore, a 121 
persistent Pseudomonas-dominated throat microbiota (community type III) was observed in three 122 
patients (p02, p03 and p04). These results indicate that the change of the respiratory microbiome 123 
might be closely associated with the disease progression in COVID-19 patients.  124 
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 125 
Gut microbiome dynamics in COVID-19 126 
To expand the scope of this research, a total of 1,940 ASVs were recovered from the 16S-rRNA 127 
gene sequences of all anal swabs, representing 13 known phyla including 182 known genera 128 
(Supplementary Table S1). The gut microbial communities of COVID-19 patients formed three 129 
distinct community types I-III (Fig. 2a-b). The richness and evenness of the gut microbiome 130 
decreased from type I to III (Fig. 2c). Indicator analyses showed that type I was primarily 131 
characterized by healthy gut bacteria including Bacteroides genus and several known butyrate-132 
producing bacteria (e.g. Faecalibacterium, Roseburia, Blautia, and Coprococcus) and one 133 
opportunistic pathogenic bacterium (Finegoldia) (Fig. 2d)21-27. The indicators of type II mainly 134 
contain various pathogenic or opportunistic pathogenic bacteria (e.g. Neisseria and Actinomyces). In 135 
community type III, the gut microbiota was dominated by Pseudomonas, implying a severe dysbiosis. 136 
We also used the gut community types I-III to reflect the progressive worsening of the microbiome.  137 
A shift of the gut microbiome from the lower-diversity community type (II or III) towards a 138 
higher-diversity type (I or II) was observed over time in 8/10 patients who had anal swabs at different 139 
time points (Fig. 2e). Accompanied with the shift, a clear trend of increase of bacterial diversity and 140 
the relative abundance of beneficial commensals (e.g. Bacteroides and Faecalibacterium) was 141 
observed in the gut microbiota from early to late stages of COVID-19 (Supplementary Fig. S3), 142 
indicating the restoration of gut microbiota. Only one patient had a reverse shift from higher-diversity 143 
type II to lower-diversity community type III.  144 
 145 
Association between the respiratory and gut microbiomes in COVID-19 146 
Most paired throat and anal swabs showed the same or similar community type levels (Fig. 3a). 147 
In particular, the direction of shift over time of the microbiome appeared to match between the throat 148 
and the gut in 7/8 patients who had two or more paired specimens at different time points (Fig. 3a). 149 
Synchronous improvements of both the respiratory and gut microbiomes from early lower-diversity 150 
community type towards late higher-diversity type occurred in six patients (p05, p17, p13, p11, p25 151 
and p29). One patient (p33) showed an improved respiratory microbiome but a stable gut community 152 
type on day 24. Only one case (p07) had a worsen gut microbiome from day 24 to day 35 but remained 153 
a stable respiratory community type. These results suggested that the microbial community dynamics 154 
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of either niches may reflect disease development and flora restoration. Because of no available anal 155 
specimens, we were unable to assess whether the gut microbiota, like the respiratory microbiota, 156 
shifted from higher-diversity type to lower-diversity type over time in this severe case (p09) (Fig. 1e). 157 
Except for the duration of COVID-19, the respiratory and gut microbial community divergence 158 
seemed not to be significantly correlated with age, gender, antibiotics use, and detection of SARS-159 
CoV-2 RNA (Supplementary Figs. S4 and S5).  160 
 We further assessed the changes of the relative abundance of several representative bacteria, 161 
including two probiotics (i.e. Bifidobacterium and Faecalibacterium), and five pathogenic bacteria 162 
(Fig. 3b). The relative abundances of Bifidobacterium and Faecalibacterium appeared to be 163 
negatively correlated with the relative abundance of the five pathogenic bacteria. An obvious decrease 164 
in the relative abundance of pathogenic bacteria was accompanied by the restoration of the respiratory 165 
and gut microbiome over time in five patients having three or more longitudinal samples (Fig.3b 166 
upper panel and Supplementary Fig. S2-S3). Moreover, significantly decreased abundance of 167 
Pseudomonas was observed in both organs in another two patients (p23 and p29). The relative 168 
abundance of Pseudomonas increased in the only patient (p07) who had a worsening gut microbiome.  169 
 170 
Bacteria–bacteria co-occurrence networks 171 
There were four indicator bacteria genera (Porphyromonas, Neisseria, and Fusobacterium in 172 
type II and Pseudomonas in type III) in the throat microbiomes that had been identified as the 173 
indicators of gut microbial community types II and III in COVID-19 patients (Supplementary Fig. 174 
S6). Apart from the shared indicators, oropharyngeal pathogenic bacteria Capnocytophaga and 175 
Actinomyces were also identified as indicators of the gut microbial community type II (Figs. 1d and 176 
2d)28,29. Because community types II and III often appeared in the early stage of COVID-19 (Figs. 1e 177 
and 2e), the appearance of these oropharyngeal bacteria in the gut suggested that a cross-talk between 178 
the respiratory and gut microbiomes occurred by frequent bacterial translocation during the early 179 
stage.  180 
To further investigate the association between the respiratory and gut microbiomes, we 181 
performed co-occurrence network analysis using paired specimens from 13 patients. Significantly 182 
positive interactions between the respiratory and gut microbiota were observed (FDR-adjusted 183 
P<0.05 and spearman correlation r > 0.7), despite obvious separations of co-occurrence patterns 184 
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between different community types (Fig. 4). There were four patterns of co-occurrence networks 185 
(Throat-IV, Throat-III, II-II and I-I) that had been identified, and only bacteria from the same 186 
community types formed significant co-occurrence networks regardless of whether they were in the 187 
throat or gut. Under the dysbiosis condition, a few dominant pathogenic bacteria (e.g. 188 
Saccharibacteria incertae sedis, Rothia and Pseudomonas) mediated the bacterial interactions, and 189 
drove the oropharyngeal bacterial translocation to the gut possibly due to increased mucosal 190 
permeability of the damaged airway and gut (Fig. 4: Throat-III and Throat-IV). Some beneficial 191 
bacteria from Firmicutes are the primary colonizers to prevent immune-mediated diseases21. 192 
Accompanied with the increase of bacteria diversity, more gut bacteria started to interact with throat 193 
microbiota, and some beneficial commensals (mainly Firmicutes) occupied the niches of the throat 194 
and gut mucosa to compete with the pathogenic bacteria (Fig. 4: II-II), leading to a possible restoration 195 
of the damaged microbiota in both organs. At the late stage of COVID-19, the species from Firmicutes 196 
and Bacterioidetes dominated the bacterial community in both organs (Fig. 4: I-I). In particular, the 197 
appearance of various probiotics (e.g. Bifidobacterium and Faecalibacterium) in both the throat and 198 
gut implied further improvement and restoration of the respiratory and gut microbiomes25,30. 199 
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Discussion 200 
Whether SARS-CoV-2 infection alters microbiota to affect COVID-19 disease progression is an 201 
important question that needs answers. In this study, we made three major observations. First, the 202 
respiratory and gut microbiota compositions of COVID-19 adults can be characterized by four (I- IV) 203 
and three (I-III) community types, respectively, and these types reflect different levels of balance 204 
between the near-normal microbiota (type I) and dysbiosis (type III/IV). Second, lower-diversity 205 
community types III/IV often appears in the early phase of COVID-19, and a consistent pattern of 206 
shift from early dysbiosis towards late near-normal coincides with the recovery of both the respiratory 207 
and gut microbiomes in most patients with mild COVID-19. Third, the shift of community types is 208 
synchronous in the respiratory tract and gut.  209 
SARS-CoV-2 infects cells through ACE2 receptor2, which is highly expressed in respiratory and 210 
intestinal epithelial cells31. SARS-CoV-2 infection can trigger the cytokine storm, cause local 211 
pathological damage32,33. As an open system with direct contact with environment and the primary 212 
site for respiratory infections, the respiratory tract microbiota is more easily affected by SARS-CoV-213 
2 infection, but has not been examined yet. We observed alterations of the respiratory microbiota in 214 
COVID-19 adults, and presented data on the dynamic change of the respiratory microbiome 215 
composition over time. The respiratory microbiome of the COVID-19 adults was characterized by 216 
four bacterial community types I-IV, which reflect the different levels of the normal microbiome to 217 
dysbiosis. The community type III dominated by Pseudomonas and type IV enriched for other three 218 
pathogenic bacteria often appeared in early throat specimens (e.g. first several days after symptom 219 
onset), indicating SARS-CoV-2 infection results in a very rapid dysbiosis in respiratory tract. A 220 
restoration of the respiratory microbiome from dysbiosis towards near-normal was observed over 221 
time in some with mild disease, whereas prolonged or worsening microbiome appeared in a few 222 
others including the only one severe case (p09). The inconsistency indicates that the diversity 223 
characteristics of the respiratory microbiome had been affected by COVID-19.  224 
Intestinal enterocytes that express ACE2 are also the target of SARS-CoV-2 which further up-225 
regulates the expression of ACE2, leading to a longer viral RNA shedding time in the gut than 226 
respiratory tract11,31. The baseline microbiome composition with abundant pathogenic bacteria (e.g. 227 
Coprobacillus, Clostridium ramoaum and Clostridium hathewayi) had been associated with the fecal 228 
levels of SARS-CoV-2 and COVID-19 severity in a previous study31. However, the sampling time 229 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 22, 2020. ; https://doi.org/10.1101/2020.07.21.20158758doi: medRxiv preprint 
was relatively late in that study (about 14 days after symptom onset), therefore unable to determine 230 
whether the baseline microbiome status is a consequence of SARS-CoV-2 infection, or a cause of 231 
disease severity. We also observed alterations of the gut microbiota during COVID-19 in adults, and 232 
found some pathogenic bacteria (e.g. Streptococcus, Rothia, Veillonella, Actinomyces, Bacteroides 233 
and Actinomyces) similar to those reported in the previous observations13,14. However，distinct from 234 
the previous studies, three community types I-III were identified to characterize the changes of gut 235 
microbiome over time, and low-diversity community types II and III often appeared in early 236 
specimens, supporting the early effect of SARS-CoV-2 on the microbiome. A fast restoration with 237 
the community type shifted from low-diversity type II to high-diversity type I over time was observed 238 
in at least 4 patients. Moreover, the Pseudomonas-dominated community type III appeared in earlier 239 
specimens of patients, and showed a slow improvement towards community II in three patients. Of 240 
particular importance is that temporal dynamic changes of the respiratory and gut microbiomes 241 
matched with each other extremely well, indicating a close association in microbiota between both 242 
body sites, possibly via the “airway-gut axis”34.  243 
The reason for the fast dysbiosis in both the respiratory tract and gut of patients with COVID-244 
19 might be that the early-stage inflammation induced by SARS-CoV-2 infection damages the 245 
mucosal tissues in airway, lung and gut7,35, and results in a fast loss of beneficial commensals, which 246 
then augments the colonization and growth of pathogens (Supplementary Fig. S7). The use of 247 
empirical antibiotics in some patient during the early stages of the pandemic may exacerbate the 248 
dysbiosis in the respiratory tract and gut. Therefore, the microbiome composition with enrichment of 249 
pathogenic bacteria (e.g. Pseudomonas and Neisseria) was observed in both throat and gut 250 
microbiomes during the first several days after symptom onsets. Because the respiratory tract is more 251 
receptive to both exogenous and indigenous microbes than the gut7,36, the dysbiosis of respiratory 252 
microbiome appeared to be worse and occurred earlier than that of the gut microbiota, as manifested 253 
by lower diversity and richness and more indicators of presumed pathogenic bacteria in the former 254 
than in the latter. During this early phase, the damaged respiratory tract mucosa enables some invasive 255 
respiratory pathogenic bacteria to be translocated to the gut, worsening the gut bacterial community 256 
(Supplementary Fig. S7).  257 
Gut microbiota plays an important role in human health by shaping local immunity and 258 
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remodeling mucosal tissues37. It is relatively more stable and plastic than the respiratory microbiota, 259 
and it may affect the latter by cross-talk between these two organs along the airway-gut axis34,36, as 260 
determined by the significantly positive co-occurrence relationship between the bacteria of the gut 261 
and respiratory tract. In spite of longer duration of SARS-CoV-2 shedding in the gut than in the 262 
respiratory tract, gut microbiota appeared to have a faster restoration with an increased bacterial 263 
diversity and enrichment of beneficial commensals than the respiratory microbiota. The former then 264 
promoted the restoration of the latter via bacterial cross-talk, and resulted in a synchronous restoration 265 
of both organs (Fig. 3b, Supplementary Figs. S2 and S3).  266 
There are at least three major stages reflecting the restoration or worsening of the microbiome 267 
in COVID-19 adults. The restoration of the microbiome seemed to be independent of early 268 
microbiome community types. For example, several patients remained microbiome community type 269 
II for a long time. Age, gender and antibiotics use seemed not to be linked to restoration of the 270 
microbiome (Supplementary Fig. S4-S5), implying potential contributions from other factors such as 271 
diet and genetic background.  272 
We noted that Pseudomonas-dominated bacterial community type III was difficult to restore 273 
towards higher-diversity community types in the respiratory tract. Pseudomonas is a well-known 274 
pathogenic bacterium, and rarely found in healthy individuals. The identification of early microbiome 275 
dysbiosis community type III or IV dominated by Pseudomonas, Rothia, and Saccharibacteria in 276 
COVID-19 patients might imply a need for microbiota-based personalized antibiotics treatment 277 
against these specific pathogens. The community type II represents a crucial intermediate stage during 278 
the restoration of the microbiome from dysbiosis towards near-normal. It was characterized by 279 
Neisseria, Fusobacterium, and Porphyromonas. Fusobacterium. Porphyromonas are the common 280 
commensals in the oropharynx and the gut18,20, while Neisseria generally presents in the lung. The 281 
appearance of lung Neisseria in both the respiratory tract and the gut, implying bacteria translocations 282 
along the “airway-lung-gut axis”. The bacteria translocations may be the consequence of increased 283 
permeability among these organs caused by local inflammation38. The Bifidobacterium and some 284 
butyrate-producing bacteria (e.g. Faecalibacterium) can improve the inflammatory conditions and 285 
regulate innate immunity by down-regulating ACE2 expression, and activating the corresponding 286 
signaling pathways25,30. During the restoration of the microbiota, these probiotics started to occupy 287 
the ecological niches in the gut and respiratory tract in the type II stage, and governed the microbial 288 
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communities in both organs by mass replacement of pathogenic bacteria (e.g. Rothia and Neisseria) 289 
in the type I stage (Fig. 3b and Supplementary Fig. S7). However, a progressively worsening in the 290 
respiratory and gut microbiome might be associated with severe cases of COVID-19.  291 
In summary, we revealed for the first time the associations between the respiratory and gut 292 
microbiota and COVID-19 disease progression, and observed early dysbiosis towards later restoration 293 
to near-normal microbiota in a proportion of adults with mild COVID-19. In the absence of specific 294 
antiviral drugs and vaccines for COVID-19, our findings have important clinical implications. First, 295 
some indicator bacteria (e.g. pathogenic pseudomonas and beneficial butyrate-producing bacteria) 296 
can be used as crucial biomarkers for clinical treatment decision making and prognostic markers. The 297 
measurement of predominant short-chain fatty acid (especially butyrate) concentration in fecal 298 
samples will be particularly useful in early clinical diagnosis. Second, apart from the routine treatment 299 
efforts (e.g. non-specific antiviral and supportive treatments)39, precision intervention and modulation 300 
of the gut and respiratory microbiota may open up novel therapeutic alternatives, such as personalized 301 
antibiotics therapy to inhibit certain pathogenic bacteria (e.g. pseudomonas). Third, COVID-19 302 
tailored probiotics (e.g. Bifidobacterium and Faecalibacterium), prebiotics (e.g. xylooligosaccharide) 303 
treatment, or symbiotic treatments might be applied to modulate the gut and respiratory microbiota 304 
to facilitate the recovery of COVID-19 patients. Lastly, fecal microbiota transplantation may be 305 
considered as another treatment choice.  306 
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Methods 307 
Study population 308 
A total of 63 subjects, including 35 laboratory-confirmed COVID-19 patients, 10 SARS-CoV-2 309 
negative patients with various diseases (non-COVID-19) and 15 healthy adults were enrolled in this 310 
study. Demographic and clinical characteristics of these patients were provided in Supplementary 311 
Table S2 and S340. Specimens including throat swabs and anal swabs were collected from the patients 312 
during hospitalization (10-40) at Nantong Third Hospital Affiliated to Nantong University and from 313 
healthy adults when they visited the same hospital for physical examination. Sampling was performed 314 
using flexible, sterile, dry swabs, which can reach the posterior oropharynx and anus easily 315 
(approximately 2 inches) by the professionals at the hospital. At least two throat swabs at different 316 
days were available for 32 of 38 COVID-19 patients (Supplementary Fig S1).  317 
The study was approved by Nantong Third Hospital Ethics Committee (EL2020006: 28 318 
February 2020). Written informed consents were obtained from each of the involved individuals. All 319 
experiments were performed in accordance with relevant guidelines and regulations.  320 
 321 
Confirmation of COVID-19 patients  322 
COVID-19 was diagnosed in adult patients according to the National Guidelines for Diagnosis 323 
and Treatment of COVID-19. The virus RNA was extracted from all samples using a Mag-Bind RNA 324 
Extraction Kit (MACCURA, Sichuan, China) according to the manufacturer’s instructions. Then the 325 
ORFlab and N genes of SARS-CoV-2 was detected using a Novel Coronavirus (2019-nCoV) Real 326 
Time RT-PCR Kit (Liferiver, Shanghai, China) according to the manufacturer’s instructions. Only the 327 
individuals who had at least two consecutive throat swabs been positive for both ORFlab and N genes 328 
of SARS-CoV-2 were defined as COVID-19 patients. All positive specimens of COVID-19 patients 329 
were confirmed by Nantong Center for Disease Control and Prevention (CDC) using recommended 330 
real-time RT-PCR assay by China CDC.  331 
 332 
16S rRNA gene sequencing 333 
Bacterial DNA was extracted from the swabs using a QIAamp DNA Microbiome Kit (QIAGEN, 334 
Düsseldorf, Germany) according to the manufacturer’s instructions, and eluted with Nuclease-free 335 
water and stored at -80℃ until use. The V4 hypervariable region (515-806 nt) of the 16S rRNA gene 336 
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was amplified universal bacterial primers41. To pool and sort multiple samples in a single tube of 337 
reactions, two rounds of PCR amplifications were performed using a novel triple-index amplicon 338 
sequencing strategy as described previously42. The first round of the PCR (PCR1) amplification was 339 
performed with a reaction mixture containing 8 μL Nuclease-free water, 0.5 μL KOD-Plus-Neo 340 
(TOYOBO, Osaka Boseki, Japan), 2.5 μL of 1 μM PCR1 forward primer, 2.5 μL of 1 μM PCR1 341 
reverse primer, and 5 μL DNA template. The products of the PCR1 reactions were verified using a 342 
1.5% agarose gel, purified using Monarch DNA Gel Extraction Kit (New England Biolabs, Ipswich, 343 
MA, USA), and quantified by a Qubit® 4.0 Fluorometer (Invitrogen, Carlsbad, CA, USA). Equal 344 
amounts of purified PXR1 products were pooled, and subjected to the secondary round of PCR (PCR2) 345 
amplification. The PCR2 was performed with a reaction mix containing 21 μL Nuclease-free water, 346 
1 μL KOD-Plus-Neo (TOYOBO, Osaka Boseki, Japan), 5 μL of 1 μM PCR2 forward primer, 5 μL of 347 
1 μM PCR2 reverse primer, and 5 μL pooled PCR1 products. The PCR2 products were verified using 348 
a 2% agarose gel, purified using the same Gel Extraction Kit and qualified using the Qubit® 4.0 349 
Fluorometer. The amounts of the specific product bands were further qualified by Agilent 2100 350 
Bioanalyzer (Agilent, Santa Clara, CA, USA). Equal molars of specific products were pooled and 351 
purified after mixing with AMPure XP beads (Beckman Coulter, Pasadena, CA, USA) in a ratio of 352 
0.8:1. Purified amplicons were paired-end sequenced (2x250) using Illumina-P250 sequencer.  353 
 354 
Bioinformatic analysis of 16S rRNA gene sequence data  355 
Sequenced forward and reverse reads were merged using USEARCH11 software43, then de-356 
multiplexed according to known barcodes using FASTX-Toolkit44. After trimming barcode, adapter 357 
and primer sequences using USEARCH11, 19,096,003 sequences were retained with an average of 358 
105508 sequences per sample. Samples with sequence <1000 were excluded from the following 359 
analysis. 360 
Because traditional OTU (operational taxonomic units) picking based on a 97% sequence 361 
similarity threshold may miss subtle and real biological sequence variation45, several novel methods 362 
such as DADA246 and Deblur47 were developed to resolve sequence data into single-sequence 363 
variants. Here, the DADA2 was employed to perform quality control, dereplicate, chimeras remove 364 
on Qiime2 platform48 with default settings except for truncating sequence length to 250bp. Finally, 365 
an amplicon sequence variant (ASV) table, equivalent to OTU table, was generated and then spitted 366 
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into gut ASV table (2348 ASVs) and throat ASV table (4050 ASVs). The taxonomic classification of 367 
ASV representative sequences was conducted by using the RDP Naive Bayesian Classifier 368 
algorithm49 based on the Ribosomal Database project (RDP) 16S rRNA training set (v16) database50. 369 
To eliminate sequencing bias across all samples, both the gut ASV table and throat ASV table were 370 
subsampled at an even depth of 4700 and 3000 sequences per sample, respectively. The ASV coverage 371 
of 82.6% (gut) and 77.2% (throat) were sufficient to capture microbial diversity of both sites. 372 
 373 
Identification and characterization of microbial community types  374 
Dirichlet multinomial mixtures (DMM)51 is an algorithm that can efficiently cluster samples 375 
based on microbial composition, its sensitivity, reliability and accuracy had been confirmed in many 376 
microbiome studies52-54. DMM clustering were conducted with bacterial genus abundance from throat 377 
and gut microbiota using the command “get.communitytype” introduced by v1.44.1 of mothur55. The 378 
appropriate microbial community type numbers (DMM clusters) were determined based on the lowest 379 
Laplace approximation index. According to sample counts per cluster, the fisher exact test was applied 380 
to discover significant associations between each cluster and host conditions (such as healthy controls, 381 
COVID-19 patients, and Non-COVID-19 patients) under P values that are below 0.05 adjusted by 382 
the False Discovery Rate (FDR). Conjugated with the Analysis of Similarities (ANOSIM), the 383 
reliability of DMM clustering was further validated and then visualized by the Non-metric 384 
multidimensional scaling (NMDS) based on the Bray-Curtis distance under bacterial genus level. 385 
“The ANOSIM statistic “R” compares the mean of ranked dissimilarities between groups to the mean 386 
of ranked dissimilarities within groups. An R value close to “1.0” indicates dissimilarity between 387 
groups, whereas an R value close to “0” indicates an even distribution of high and low ranks within 388 
and between groups”. The ANOSIM statistic R always ranges between −1 to 1. The positive R values 389 
closer to 1 suggest more similarity within sites than between sites, and that close to 0 represent no 390 
difference between sites or within sites56. ANOSIM p values that are lower than 0.05 imply a higher 391 
similarity within sites. Richness (Observed OTUs/ASVs) and Pielou's or Species evenness for each 392 
community type were calculated for estimating the difference of alpha diversity. The analyses of alpha 393 
diversity, NMDS and ANOSIM were performed using R package “vegan” v2.5-6. Dynamic change 394 
of community types was showed according to collected dates of specimens with R package ‘P 395 
heatmap’. For association between community types and potential confounding factors such as sex, 396 
age, virus existence and antibiotic use, the fisher exact test based on sample count was performed and 397 
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the association with FDR-corrected p value <0.05 was considered significant.  398 
 399 
Indicator analysis in throat and gut community types 400 
According to the definition given by the United Nations Environment Programme (1996), the 401 
indicator species are a group of species whose status provides information on the overall condition of 402 
the ecosystem and of other species in that ecosystem, reflecting the quality and changes in 403 
environmental conditions as well as aspects of community composition. To obtain the reliable 404 
indicator genus that is specific to each community type, we performed the Indicator Species Analysis 405 
using the indicspecies package (ver.1.7.8) 57 in R platform with top 30 genus contributing to DMM 406 
clustering in both throat (accounting for 66% cumulative difference) and gut (68% cumulative 407 
difference). Dynamic changes of indicator genera corresponding to each throat community type were 408 
showed in all COVID-19 patients using the pheatmap package in R and only gut indicator genera 409 
with indicator values that were above 0.05 were presented in the patients. 410 
 411 
Co-occurrence network analysis of a crosstalk between throat and gut microbiota 412 
Based on microbial genus abundances of both throat and gut samples collected from 13 COVID-413 
19 patients at the same time point, we calculated the Pearson Correlation Coefficient (Pearson’s r) 414 
among the throat & gut microbial genera. The Pearson’s r with P values that were below 0.05 after 415 
the FDR adjustment were considered significant correlations. Co-occurrence network of significantly 416 
correlated microbial genus pairs was visualized using Cytoscape v3.8.058. 417 
 418 
Data availability 419 
The raw data of 16S rRNA gene sequences are available at NCBI Sequence Read Archive (SRA) 420 
(https://www.ncbi.nlm.nih.gov/sra/) at BioProject ID PRJNA639286. 421 
 422 
Supplemental information 423 
Supplemental information includes supplemental Experimental Procedures, six figures, and three 424 
tables and can be found with this article. 425 
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Figure legends 566 
Figure 1. DMM clustering of 16S rRNA gene sequencing data of throat microbiota (N = 112). 567 
Dirichlet multinomial mixtures (DMM) modelling was applied to 16S rRNA gene sequencing. The 568 
entire dataset formed six distinct clusters based on lowest Laplace approximation. Bacterial taxa 569 
marked by the stars represent unclassified bacteria genera. 570 
a. Heat map showing the relative abundance of the 30 most dominant bacterial genera per DMM 571 
cluster. The stars represent unclassified genera. NP, enriched in Non-COVID-19 patients. H, enriched 572 
in Healthy individuals. I-IV enriched in COVID-19 patients. 573 
b. Nonmetric multidimensional scaling (NMDS) visualization of DMM clusters using Bray-Curtis 574 
distance of throat bacterial genera. The ANOSIM statistic R closer to 1 with < 0.05 P value suggest 575 
significant separation of microbial community structures. The stress value that was lower than 0.2 576 
provides a good representation in reduced dimensions. 577 
c. Box plots showing the alpha diversity (richness and evenness) per each DMM cluster. 578 
d. Indicators of airway microbial community types (DMM clusters) identified from top 30 genus 579 
contributing to throat microbial community typing (DMM clustering) in a. * P <0.05, ** P <0.01, and 580 
*** P < 0.001. 581 
e. Dynamic shift of four throat microbial community types (DMM clusters) in different COVID-19 582 
stages. Empty boxes indicate samples were unavailable in COVID-19 patients. Ages (years) were 583 
shown in parenthesis. NA, unavailable. 584 
 585 
Figure 2. DMM clustering of 16S rRNA gene sequencing data of gut microbiota (N = 45). 586 
Dirichlet multinomial mixtures (DMM) modelling was applied to 16S rRNA gene sequencing. The 587 
entire dataset formed three distinct clusters based on lowest Laplace approximation. All samples were 588 
collected from COVID-19 patients. Bacterial taxa marked by the stars represent unclassified bacteria 589 
genera. 590 
a. Heat map showing the relative abundance of the 30 most dominant bacterial genera per DMM 591 
cluster. 592 
b. Nonmetric multidimensional scaling (NMDS) visualization of DMM clusters using Bray-Curtis 593 
distance of gut bacterial genera. The ANOSIM statistic R closer to 1 with < 0.05 P value suggest 594 
significant separation of microbial community structures. The stress value that was lower than 0.2 595 
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provides a good representation in reduced dimensions. 596 
c. Box plots showing the alpha diversity (richness and evenness) per each DMM cluster. 597 
d. Indicators of gut microbial community types (DMM clusters) identified from top 30 genus 598 
contributing to gut microbial community typing (DMM clustering) in a. * P <0.05, ** P <0.01, and 599 
*** P < 0.001. 600 
e. Dynamic shift of gut microbial community types (DMM clusters) in different COVID-19 stages. 601 
Empty boxes indicate samples were unavailable in COVID-19 patients. Ages (years) were shown in 602 
parenthesis. 603 
 604 
Figure 3. Dynamic change of both DMM clusters (a) and seven key taxa (b) in respiratory tract 605 
and gut of patients with mild COVID-19  606 
a, Co-variation dynamics of throat and gut microbial communities of 13 COVID-19 patients. Filled 607 
circles indicate the presence of microbial community types. Positive or Negative detections of SARS-608 
-CoV-2 in gut or throat are implicated by + or - symbols, respectively. Age (months) of each COVID-609 
19 adult was shown in brackets.  610 
b, key taxa of DMM clusters were shown in nine mild COVID-19 adults with at least two time points 611 
of sampling. Linked to Fig.1a, Fig.2a, and Supplementary Figs.2-3. 612 
 613 
Figure 4. Co-occurrence networks of gut and throat microbiota within 13 COVID-19 patients. 614 
Pearson correlation was employed to calculate correlation coefficient (r) between bacterial genus 615 
pairs based on their relative abundances. Co-occurred pairs with r > 0.7 under FDR-adjusted P < 0.05 616 
were shown and visualized by Cytoscape version 3.8.0. Negative correlations that were not significant 617 
were not shown. Edges were sized based on r values. The stars represented unclassified bacteria 618 
genera. Four co-occurrence patterns mediated by throat-IV indicator, throat-III indicator, throat-II & 619 
gut-II indicators, and throat-I& gut-I indicators, respectively. The bigger squares or circles were 620 
indicators in Figs. 1d and 2d.  621 
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Supplementary materials 622 
Supplementary table S1. Throat and gut microbial abundances (phyla and genera). 623 
 624 
Supplementary table S2. Clinical index of COVID-19 patients in this study. 625 
 626 
Supplementary table S3. Demographic information of COVID-19 patients in this study. 627 
 628 
Supplementary figure S1. COIVD-19 patient admission and discharge time as well as the point 629 
of detection of SARS-CoV-2. a. the hospitalization of p13 was 40 days. b. the information of these 630 
patients was unavailable. DAY 1 was the day of symptom onset. 631 
 632 
Supplementary figure S2. Time-scale changes of indicators of throat microbial community 633 
types. Color sectors represent relative abundance of indicators in different COVID-19 stages. Linked 634 
to Figure 1. 635 
 636 
Supplementary Figure S3. Time-scale changes of indicators of gut microbial community types. 637 
Color sectors represent relative abundance of indicators in different COVID-19 stages. Linked to 638 
Figure 2. 639 
 640 
Supplementary Figure S4. Enrichment analysis of impact factors on throat microbial 641 
community typing. a) Sex, b) Age, c) Virus detection, and d) Antibiotic uses. Enrichment analysis 642 
was performed by using the Fisher’s exact test under FDR-adjusted P < 0.05. Sample numbers were 643 
shown on the bar. Only COVID-19 patients were used for this analysis. 644 
 645 
Supplementary Figure S5. Enrichment analysis of impact factors on gut microbial community 646 
typing. a) Sex, b) Age, c) Virus detection, and d) Antibiotic uses. Enrichment analysis was performed 647 
by using the Fisher’s exact test under FDR-adjusted P < 0.05. No significant enrichment was observed. 648 
Sample numbers were shown on the bar. 649 
 650 
Supplementary Figure S6. Comparisons of indicator genera between throat and gut microbial 651 
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clusters. 652 
 653 
Supplementary Figure S7. Putative restoration model of the respiratory and gut microbiomes 654 
over time in adults with mild COVID-19. SARS-CoV-2 infection resulted in a fast dysbiosis in 655 
both the respiratory tract and gut at the very early phase of the disease. A fast restoration of both the 656 
respiratory and gut microbiomes from early dysbiosis towards late near-normal status was observed 657 
in most adults with mild COVID-19 albeit they seemed to have a relatively slow clinical recovery. 658 
This model reflects the major microbiome dynamic change in most adults with mild COVID-19 but 659 
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